Abstract. Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal diseases, and the median survival time is very short. Upregulation of hedgehog signaling pathway activity is a vital factor in pathogenesis of PDAC. However, as a negative regulator of hedgehog signaling, it is not very clear what role the suppressor of fused (SUFU) plays in PDAC tissue. In our study for the identification of alternative splicing transcripts of SUFU gene in human PDAC cells, a novel transcript variant of SUFU (SUFUvN) was discovered by 3' rapid amplification of cDNA ends (3'RACE) and cDNA clone. SUFUvN contained an additional new protein-coding exon compared with the transcript variant 1 of SUFU (SUFUv1, NM_016169) published in NCBI website. The sequence of the new protein-coding exon was the same as a fragment of intron between exon 10 and 11 of SUFUv1. Thus, an exon skipping occurred in transcription of SUFUv1. Compared with the expression vector of SUFUvN transfected PDAC cells, the corresponding protein expression encoded by SUFUvN (SUFU isoform N) was detected in PDAC tissue. Furthermore, it was observed that elevated SUFUvN transcription level was related with lymph node metastasis in PDAC tissues, while neither SUFUv1 nor transcript variant 2 of SUFU (SUFUv2, NM_001178133) did. Our data indicate that there exists a novel transcript variant of SUFU which can be transcribed and translated into corresponding protein and its transcription is related with metastasis of lymph nodes in PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC), also known as pancreatic cancer is one of the most fatal diseases, and the overall 5-year survival rate among patients with pancreatic cancer is <5%. In pancreatic cancer, 90% of tumors have activating mutations in the KRAS2 oncogene (1) . In addition, activation of hedgehog signaling pathway is vital in tumor development. Activity of hedgehog signaling pathway is gradually increased in the progress from pancreatic intraepithelial neoplasia (PanIN) to PDAC (2) (3) (4) . Mutations of components lead to activation of hedgehog signaling pathway in some types of tumors (5) (6) (7) (8) . However, no mutations have been detected in components of this pathway in pancreatic cancer. SUFU is an essential negative regulator of mammalian hedgehog signaling pathway. Kasai et al (9) provided evidence that physical binding inhibition of GLI1 by SUFU is dismissed by tethering of SUFU in the cytoplasm of PDAC cells by overexpressed SCL/TAL1 interrupting locus (SIL) and KRAS mutation. However, Chen et al (10) provided convincing data indicating that mouse Sufu sequesters Gli2/3 protein in the cytoplasm and protects them from Spop-mediated protein degradation, providing a Gli protein pool for the production of Gli2/3 activators and repressors. Sufu is necessary for maximal activation of hedgehog pathway. Thus Sufu has an unexpected positive role in controlling mammalian hedgehog signaling. Thus, we proceeded to clarify the function of SUFU in human pancreatic cancer. There are two transcript variants of SUFU published in NCBI website: transcript variant 1 of SUFU (SUFUv1, NM_016169) and transcript variant 2 of SUFU (SUFUv2, NM_001178133). We started by making cDNA clones of alternative splicing transcript variants of SUFU gene in human pancreatic cancer cells.
Materials and methods
Cell culture and RNA extraction. Seven pancreatic cancer cell lines SW1990, PATU8988, AsPC-1, BxPC-3, CFPAC-1, Capan-2, PANC-1 were cultured in DMEM medium supplemented with 10% FBS and incubated in a 5% CO 2 humidified incubator at 37˚C. Total RNA was extracted from cells using RNA iso Plus (Takara, Japan) according to the manufacturer's instructions. The yield of RNA was determined using a spectrophotometer (NanoDrop 2000, Thermo Scientific, USA) and the integrity was evaluated using agarose gel electrophoresis stained with ethidium bromide.
3' rapid amplification of cDNA ends (3'RACE) and nested PCR. Two reference sequence transcript variants of SUFU gene are published on NCBI. They are transcript variant 1 of SUFU (SUFUv1, NM_016169) and transcript variant 2 of SUFU (SUFUv2, NM_001178133). 3'RACE was made to obtain the 3' cDNA of SUFU transcripts.
3'-Full RACE Core Set ver.2.0 (product code, D314, Takara) kit contains: 3'RACE adaptor (a reverse transcription primer adaptor which can addict to mature mRNA poly A tail by its poly T sequences), M-MLv reverse transcriptase, 3'RACE outer primer (reverse primer of the first nested PCR), 3'RACE inner primer (reverse primer of the second nested PCR), etc. The steps are shown in Fig. 1A .
We performed reverse transcription. The reaction consisted of 1 µl total RNA (500 ng/µl), 1 µl 3'RACE adaptor, 0.25 µl M-MLv reverse transcriptase, 0.25 µl RNase inhibitor, 2 µl 5X M-MLv buffer, 1 µl dNTP mixture and 4.5 µl RNase-free dH 2 O, in a total volume of 10 µl. Reaction was performed in a GeneAmp ® PCR System 9700 (Applied Biosystems, USA) for 60 min at 42˚C, followed by heat inactivation of RT for 15 min at 70˚C.
First cycle of nested PCR. The forward primer of the first nested PCR was designed by us according to the kit instructions (Table Ⅰ) . We call this forward primer P1. It is situated in the 9th exon of SUFUv1. The first base pair of P1 is situated in the 1,218 bp of the whole RNA sequences. The reverse primer of the first nested PCR is in the kit called 3'RACE outer primer. The reaction consisted of 3 µl reverse transcription product, 7 µl 1X cDNA dilution buffer, 2 µl P1 (10 µmol/l), 2 µl 3'RACE outer primer, 5 µl 10X Ex Taq buffer (including Mg 2 ), 0.25 µl Ex Taq enzyme and 30.75 µl dH 2 O. Reactions were performed in a GeneAmp PCR System 9700 for 3 min at 94˚C, followed by 25 cycles of 94˚C for 30 sec, 55˚C for 30 sec, 72˚C for 5 min, and a last step of 72˚C for 10 min.
Second cycle of nested PCR. The forward primer of the second nested PCR was also designed by us according to the kit instruction (Table Ⅰ) . We call this forward primer P2. It is situated in the 10th exon of SUFUv1. The first base pair of P2 is situated in the 1,357 bp of the whole RNA sequences. The reverse primer of the second nested PCR is in the kit called 3'RACE inner primer. The reaction consisted of 1 µl the first nested PCR product, 8 µl dNTP mixture, 5 µl 10X Ex Taq buffer (including Mg 2 ), 0.5 µl Ex Taq enzyme, 2 µl P2 (10 µmol/l), 2 µl 3'RACE inner primer and 31.5 µl dH 2 O. Reactions were performed in a GeneAmp PCR System 9700 for 3 min at 94˚C, followed by 30 cycles of 94˚C for 30 sec, 55˚C for 30 sec, 72˚C for 5 min, and a last step of 72˚C for 10 min.
The product of second nested PCR was ligated with pMD-18T vector, and infected DH5α. Then, we selected 10 positive clones, and made sequence detection.
RT-PCR to identify the 5' cDNA sequence of novel transcript variant of SUFU (SUFUvN). We performed reverse transcription by SUFU ORF reverse transcription primer (Table Ⅰ) , then, by PCR. The forward primer of PCR was designed by us called P3 (Table Ⅰ) . It is situated in the first exon of SUFUv1. Reverse primer of PCR was also designed by us called P4 (Table Ⅰ) . It contains partial 11th exon of SUFUv1 and partial new exon. Product of PCR was used for sequence detection. The steps are shown in Fig. 1B .
Construction of expression clones of SUFUvN and SUFUv1.
The forward primer terminal is added with protection base pairs, BamHⅠ enzyme sites and Kozak sequences. The reverse primer terminal is added with protection base pairs, AgeⅠ enzyme sites. The forwad primer and reverse primer were designed to clone open reading frame (ORF) of SUFU. We performed reverse transcription by SUFU ORF reverse transcription primer (Table Ⅰ) , then by PCR. The sequence of forward primer is: 5'-cgggatccGGGATGGC GGAGCTGCGGCCTA-3'. The sequence of reverse primer is: 5'-gcgcaccggtCTAGTGTAG CGGACTGTCGAACA-3'. BamHⅠ and AgeⅠ double enzyme digestion was made in both PCR product and pcDNA3.1mychisA (+) expression vector. After ligation of PCR product with pcDNA3.1mychisA (+) expression vector and DH5α infection we selected positive clones and sequence detection was performed.
Cell transfection. SW1990 cells were transiently transfected with empty vector, SUFUv1 and SUFUvN expression vector, respectively, by use of Lipofectamine 2000 kit (Takara) according to the manufacturer's instructions. The cells were cultured for 24 h after transfection. Then the cells were harvested for further studies.
Western blotting. The empty vector, SUFUv1 and SUFUvN expression vector transfected SW1990 cells were collected. Cells were dissolved in cell lysis buffer. Protein of pancreatic cancer tissue was extracted by RIPA lysis buffer. The lysates were cooled with ice for 30 min, and then centrifuged at 13,000 x g for 30 min. Proteins (10 µg) in the collected supernatant were separated by SDS-PAGE on 12% gels and then transferred to PvDF membranes. The membrane, after a block with 5% skim milk, was incubated with primary antibodies to SUFU (rabbit anti-human monoclonal antibody, catalog no. NBP1-40515, Novus, USA) and GAPDH (ab97626, Table Ⅱ , and the probes are shown in Fig. 1C .
Quantification was performed with a two-step reaction process: reverse transcription (RT) and PCR. Each RT reaction consisted of 1 µg RNA, 2 µl of PrimerScript buffer, 0.5 µl of oligodT, 2 µl of random 6 mers and 0.5 µl of PrimerScript RT Enzyme Mix I (Takara), in a total volume of 10 µl. Reactions were performed in a GeneAmp PCR System 9700 (Applied Biosystems) for 15 min at 37˚C, followed by heat inactivation of RT for 5 sec at 85˚C. Real-time PCR was performed using LightCycler ® 480 Ⅱ Real-time PCR Instrument (Roche, Swiss) with 20 µl PCR reaction mixture that included 10 µl of 2X TaqMan mix (Takara), 1 µl of 20X probe and primers mixture (Invitrogen), 2 µl of cDNA, and 7 µl of nuclease-free water. Reactions were incubated in a 384-well optical plate (Roche) at 95˚C for 10 min, followed by 40 cycles of 95˚C for 10 sec, 60˚C for 30 sec. Each sample was run in triplicate for analysis. At the end of the PCR cycles, melting curve analysis was performed to validate the specific generation of the expected PCR product. The expression levels of mRNAs were normalized to 18s rRNA and were calculated using the 2 -∆∆Ct method. the SPSS 18.0 software package. P-values <0.05 were considered statistically significant.
Results

Identification of 3'-and 5' cDNA sequences of novel SUFU transcript variant (SUFUvN).
Following the strategy described in Fig. 1A , the 3'RACE amplification for 3' cDNA of SUFU in pancreatic cancer cells was performed. The products of first cycle (using P1 and 3'RACE outer primer) and second cycle of nested PCR (using P2 and 3'RACE inner primer) are shown in Fig. 2A . A cDNA fragment of ~1,000 bp products from SW1990 cells was cloned into pMD18-T and sequenced.
As shown in Figs. 2B and 3 , a novel cDNA fragment sequence In order to identify the full length of SUFUvN cDNA squence, the 5' cDNA fragment of SUFUvN was amplified by RT-PCR following the strategy described in Fig. 1B , in which a specific primer 4 (P4) covering the new exon and exon 11 of SUFUv1 pairing with a specific primer 3 (P3) siting in exon 1 of SUFUv1 were used. As shown in Fig. 4A , a cDNA fragment of 1,400 bp products from SW1990 cells was obtained by RT-PCR and its sequence was the same as the exon 2-exon 10 of SUFUv1 cDNA. The combination of exon 10 and new exon was also been detectable in 1,400 bp product (data not shown). Thus, the new exon is combined with exon 1-10 in 5'-terminal and with exon 11-12 in 3' terminal.
Clone of full length of SUFUvN. RT-PCR product of SUFU transcript was double enzyme digested by BamHⅠ and AgeⅠ and was ligated with expression vector pcDNA3.1mychisA (+). After infection to DH5α, positive clones were selected and sequenced. From the sequencing and alignment result (data not shown), we identified two kinds of SUFU cDNA clones. They are SUFUv1 and full length of SUFUvN as described above. (Fig. 4B) . - 
-----------------------------------------------------------------------------------------------------------------------------------------
Identification of protein expression encoded by SUFUvN (isoform N).
There were three bands present in the western blotting figure of PDAC tissue (Fig. 4C) . Compared with lanes with SUFUv1 and SUFUvN expression vector transfected SW1990 serum, two bands were identified to be protein encoded by SUFUv1 (isoform 1) and isoform N in PDAC tissues. Isoform 1 is ~54 kDa, while isoform N is ~60 kDa.
The additional band ~47 kDa may be protein encoded by SUFUv2 (isoform 2).
Detection and clinical relevance of SUFUvN in PDAC tissue.
We designed TaqMan MGB probes to identify different transcript variants of SUFU. Each probe is described in the figure, so each probe can uniquely detect the corresponding SUFU variant (Fig. 1C) . After detecting transcription levels of SUFU variants in PDAC tissues of 40 patients, we found that SUFUvN transcription levels are significantly higher in PDAC tissues of N1 stage patients than in N0 stage patients, while there is no relationship between other variants transcription levels and lymph node metastasis (Fig. 5) . As shown in Table Ⅲ , we found that the elevated transcription of SUFUvN was related with high N stage, while no correlation was found with other clinical features, including T stage, age of onset, gender, tumor size and tumor differentiation. (12) . The study found the ability of GLI binding of different SUFU isoforms will differ because of their different carboxyl terminal structure. To our knowledge, direct binding of Sufu to all three Gli transcription factors has been well documented (13) (14) (15) (16) (17) . Sufu binds Gli: the amino and carboxyl terminal of Sufu bind the carboxyl and amino terminal of Gli, respectively. Thus we hypothesize that SUFU functions mentioned in our experiment are loaded by different variants of it according to their affinity to GLI. SUFUvN is possibly a positive regulator of Hh pathway because it has more affinitive to GLI2 and GLI3, while SUFUv1 is more likely to be a negative regulator of Hh pathway because of its affinity to GLI1. So, in pancreatic cancer tissue, endogenous SUFUvN binds with GLI2/3 to antagonize their degradation. High level of endogenous SUFUvN leads to more activation of Hh pathway, and accelerates tumor metastasis.
Research reports describing gene alternative splicing variants and different function of their proteins are limited. It is partially due to the complicated and limited methods in studying splicing variant. In our study, we designed TaqMan MGB probe and primers according to the unique exon of different variants. This can distinguish transcription of different variants. Although the corresponding protein isoforms can be recognized by western blotting because of the different molecular weights, the subcellular situation of different protein isoforms can not be distinguished by immunohistochemistry stain in tissue section unless unique antibodies are produced. Recognition of subcellular situation of different isoforms is very helpful for studing their functions. Additionally, if in situ hybridization of different variant mRNA is required, new technology and method should be applied, for example the LNA probe (18, 19) . In addition, the crystal and small-angle X-ray scattering structures of full-length human SUFU and its complex with the key SYGHL motif conserved in all GLIs have been reported by Cherry et al (20) . It is demonstrated that GLI binding is associated with major conformational changes in SUFU. If alternative splicing transcription variants of SUFU including SUFUvN were to be added to their study in the future, we could improve the understanding of the affinity between SUFU variants and GLIs.
